Shen et al., 2019 - Google Patents
A conserved region of nonstructural protein 1 from alphacoronaviruses inhibits host gene expression and is critical for viral virulenceShen et al., 2019
View HTML- Document ID
- 4629507862952973219
- Author
- Shen Z
- Wang G
- Yang Y
- Shi J
- Fang L
- Li F
- Xiao S
- Fu Z
- Peng G
- Publication year
- Publication venue
- Journal of Biological Chemistry
External Links
Snippet
Coronaviruses are enveloped, single-stranded RNA viruses that are distributed worldwide. They include transmissible gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV), and the human coronaviruses severe acute respiratory syndrome coronavirus …
- 230000014509 gene expression 0 title abstract description 81
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shen et al. | A conserved region of nonstructural protein 1 from alphacoronaviruses inhibits host gene expression and is critical for viral virulence | |
| Peacock et al. | SARS-CoV-2 one year on: evidence for ongoing viral adaptation | |
| Teklue et al. | Generation and evaluation of an African swine fever virus mutant with deletion of the CD2v and UK genes | |
| Groenke et al. | Mechanism of virus attenuation by codon pair deoptimization | |
| Kumar et al. | Anti-SARS coronavirus agents: a patent review (2008–present) | |
| US20240358819A1 (en) | Pan-human coronavirus domain vaccines | |
| Xia et al. | Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation | |
| Yuan et al. | Targeting papain-like protease for broad-spectrum coronavirus inhibition | |
| Li et al. | SARS-CoV-2 vaccine candidates in rapid development | |
| US20240299531A1 (en) | Therapeutic use of sars-cov-2 mrna domain vaccines | |
| WO2022245888A1 (en) | Seasonal flu rna vaccines and methods of use | |
| Duman et al. | COVID-19 vaccine candidates and vaccine development platforms available worldwide | |
| Zheng et al. | Host cells actively resist porcine reproductive and respiratory syndrome virus infection via the IRF8-microRNA-10a-SRP14 regulatory pathway | |
| Tseng et al. | Current concepts in the development of therapeutics against human and animal coronavirus diseases by targeting NP | |
| Sakr et al. | Latest updates on SARS-CoV-2 genomic characterization, drug, and vaccine development; a comprehensive bioinformatics review | |
| EP2884998B1 (en) | Attenuated live vaccine for crimean-congo hemorrhagic fever virus and erve virus | |
| Farhana et al. | Sars-CoV-2leader-RNA-primed Transcription and RNA-Splicing prevention, control and Treatment | |
| CN115804775B (en) | Application of S63845 in preparation of medicines for resisting new coronavirus infection | |
| US9795665B2 (en) | Attenuated live vaccine for Crimean-Congo hemorrhagic fever virus and Erve virus | |
| Shahverdi et al. | Therapeutic measures for the novel coronavirus: a review of current status and future perspective | |
| Yuan et al. | Modification of the second translation initiation site restricts the replication of foot-and-mouth disease virus in PK-15 cells | |
| US20210386695A1 (en) | Use Of Disulfiram For Treating Infection Of SARS-COV-2 | |
| CN111920821B (en) | Application of tomatidine in preparation of antiviral drugs | |
| Kardani et al. | Vaccine development against SARS-CoV-2: from virology to vaccine clinical trials | |
| Krejčová et al. | Structural and functional insights in flavivirus NS5 proteins gained by the structure of Ntaya virus polymerase and methyltransferase |